Stoke Therapeutics, Inc. (STOK) Tops Q3 EPS by 8c

Stoke Therapeutics, Inc. (NASDAQ: STOK) reported Q3 EPS of ($0.55), $0.08 better than the analyst estimate of ($0.63). Revenue for the quarter came in at $3.31 million versus the consensus estimate of $3.56 million.

For earnings history and earnings-related data on Stoke Therapeutics, Inc. (STOK) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• MP Materials seen largely insulated after China export-control move
• Goldman reinstates Estee Lauder rating, sees turnaround driving growth and margins